Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 1/2 × Active not recruiting × zipalertinib × Clear all

Phase

Phase 3 1 Phase 1/2 1

Status

Active not recruiting 1

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Carcinoma, Non-Small-Cell Lung 1

Interventions

pembrolizumab 64 Nivolumab 36 Cyclophosphamide 35 Carboplatin 26 Gemcitabine 21 Paclitaxel 20 venetoclax 19 durvalumab 19 Specimen Handling 19 Lenalidomide 19 Dexamethasone 18 Rituximab 17 Magnetic Resonance Spectroscopy 17 Radiotherapy 15 fludarabine 14 Ipilimumab 14 Doxorubicin 14 atezolizumab 12 Vincristine 12 Biopsy 12 Cisplatin 11 Calcium Dobesilate 11 Bevacizumab 11 Azacitidine 11 olaparib 10 Etoposide 10 Prednisone 9 Pemetrexed 9 Oxaliplatin 9 Fluorouracil 9

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT04036682 2025-03-13

REZILIENT1

Cullinan Therapeutics Inc.

Phase 1/2 Active not recruiting

Carcinoma, Non-Small-Cell Lung

Data powered by HemOnc (CC BY 4.0) Colophon ⚡